Home Nation News Govt Panel Recommends Market Authorisation for Covovax Jab as Heterologous Booster Dose

Govt Panel Recommends Market Authorisation for Covovax Jab as Heterologous Booster Dose

0
Govt Panel Recommends Market Authorisation for Covovax Jab as Heterologous Booster Dose

Last Updated: January 12, 2023, 18:28 IST

Covovax is manufactured through technology transfer from Novavax. (Image: Twitter/@adarpoonawalla)

Covovax is manufactured by expertise switch from Novavax. (Image: Twitter/@adarpoonawalla)

The DCGI had accepted Covovax for restricted use in emergency conditions in adults on December 28, 2021, within the 12-17 age group on March 9, 2022 and likewise in kids aged 7-11 years on June 28, 2022 topic to sure circumstances

An professional panel of the central drug regulatory authority has really useful market authorisation for Serum Institute of India’s Covid vaccine Covovax as a heterologous booster dose for adults who’ve been administered two doses of Covishield or Covaxin, official sources stated on Thursday.

Prakash Kumar Singh, director (authorities and regulatory affairs) at Serum Institute of India (SII) had just lately written a letter to Drugs Controller General of India (DCGI) for approval of Covovax heterologous booster dose for these aged 18 years and above in view of escalating COVID-19 pandemic scenario in some nations, the sources stated.

“The topic professional committee (SEC) of the CDSCO on Wednesday deliberated on the difficulty and really useful for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who’ve been administered two doses of Covishield or Covaxin,” an official source said.

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022 and also in children aged 7-11 years on June 28, 2022 subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with SII for development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries.

Read all the Latest India News here

(This story has not been edited by News18 employees and is revealed from a syndicated information company feed)

Source hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here